We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+27.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.71B
AUM Growth
+$107M
Cap. Flow
-$182M
Cap. Flow %
-10.62%
Top 10 Hldgs %
37.71%
Holding
102
New
9
Increased
24
Reduced
36
Closed
9

Top Buys

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$8.04M
2
CDTX
Cidara Therapeutics
CDTX
+$7.36M
3
LENZ
LENZ Therapeutics
LENZ
+$5.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.15M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$30.4M
2
BPMC
Blueprint Medicines
BPMC
+$23.8M
3
ARGX icon
argenx
ARGX
+$21.8M
4
INSM icon
Insmed
INSM
+$17.2M
5
UNH icon
UnitedHealth
UNH
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.4B
$105M 6.15%
142,750
-33,000
-19% -$21.8M
LLY icon
2
Eli Lilly
LLY
$1.02T
$80.4M 4.7%
105,400
-11,100
-10% -$8.26M
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$6.81B
$72.4M 4.23%
717,102
-144,051
-17% -$13.4M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$10.8B
$63.2M 3.69%
137,746
-2,550
-2% -$951K
RVMD icon
5
Revolution Medicines
RVMD
$39.9B
$62.4M 3.64%
1,335,270
+4,310
+0.3% +$169K
MRUS
6
DELISTED
Merus
MRUS
$56.2M 3.28%
597,051
-466,557
-44% -$30.4M
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$6.46B
$55.8M 3.26%
761,126
-57,080
-7% -$3.63M
INSM icon
8
Insmed
INSM
$21.4B
$55.4M 3.24%
385,000
-140,000
-27% -$17.2M
TVTX icon
9
Travere Therapeutics
TVTX
$5.2B
$51.7M 3.02%
2,164,773
+256,565
+13% +$4.82M
ASND icon
10
Ascendis Pharma A/S
ASND
$16B
$42.6M 2.49%
214,500
-2,500
-1% -$466K
IRTC icon
11
iRhythm Holdings
IRTC
$3.85B
$40.4M 2.36%
235,000
-7,500
-3% -$1.19M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.79B
$38.5M 2.25%
958,542
-31,203
-3% -$1.17M
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.45B
$37.5M 2.19%
1,246,341
-144,731
-10% -$4.34M
ISRG icon
14
Intuitive Surgical
ISRG
$127B
$36.7M 2.14%
82,000
– –
BSX icon
15
Boston Scientific
BSX
$69.5B
$35.2M 2.06%
360,250
+5,250
+1% +$544K
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.06B
$34.2M 2%
851,744
-79,937
-9% -$2.82M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$27.5B
$33.9M 1.98%
74,250
-25,750
-26% -$10.5M
EXAS
18
DELISTED
Exact Sciences
EXAS
$32.5M 1.9%
593,500
+21,500
+4% +$1.07M
PEN icon
19
Penumbra
PEN
$12.7B
$30.5M 1.78%
120,500
-8,000
-6% -$2.02M
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$29.7M 1.74%
626,526
-14,000
-2% -$678K
SRRK icon
21
Scholar Rock
SRRK
$5.67B
$29.6M 1.73%
794,133
– –
ZLAB icon
22
Zai Lab
ZLAB
$2.06B
$26.8M 1.57%
791,193
-80,199
-9% -$2.76M
GPCR icon
23
Structure Therapeutics
GPCR
$3.41B
$26.6M 1.56%
951,154
-184,725
-16% -$3.68M
KYMR icon
24
Kymera Therapeutics
KYMR
$8.51B
$25.5M 1.49%
450,374
– –
THC icon
25
Tenet Healthcare
THC
$20.5B
$25.4M 1.48%
125,000
-5,000
-4% -$887K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rock Springs Capital Management held 102 positions worth $1.71B, up 6.7% from $1.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Rock Springs Capital Management withdrew a net $182M in Q3 2025, closing 9 positions and reducing 36 holdings. Its most notable exit was Blueprint Medicines, an estimated $23.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Heartflow Inc worth $8.41M.

  • Rock Springs Capital Management's largest Q3 2025 buy was Heartflow Inc: 250,000 shares worth $8.41M.
  • Rock Springs Capital Management added most to Cidara Therapeutics in Q3 2025, an estimated $7.36M increase.
  • Rock Springs Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $30.4M.
  • Rock Springs Capital Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $23.8M.
  • Rock Springs Capital Management's ten largest holdings make up 38% of its $1.71B portfolio in Q3 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 9 in Q3 2025.
  • Rock Springs Capital Management's portfolio value rose 6.7% quarter-over-quarter to $1.71B.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.